The Short And Controversial Life Of Zohydro Comes To An End

 
• By Brenda Sandburg

US FDA’s approval of the opioid over resounding opposition of an advisory committee has haunted the agency, and it has imperiled both of Robert Califf’s nominations to be commissioner. The latest company to own Zohydro stopped selling it and FDA withdrew approval of its NDA.

Zohydro ER tombstone
Zohydro (hydrocodone bitartrate) has been withdrawn from the market • Source: Nielsen Hobbs; the Pink Sheet | Alamy images

More from US FDA

More from Agency Leadership